{"version":"1.0","provider_name":"Frezza Partners","provider_url":"https:\/\/frezzapartners.com\/en\/","author_name":"Frezza Partners","author_url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/","title":"Global Oncology Trends. L\u2019ultimo report di IQVIA Institute - Frezza Partners","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"I5rCsDcsQl\"><a href=\"https:\/\/frezzapartners.com\/en\/global-oncology-trends-lultimo-report-di-iqvia-institute\/\">Global Oncology Trends. L\u2019ultimo report di IQVIA Institute<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/frezzapartners.com\/en\/global-oncology-trends-lultimo-report-di-iqvia-institute\/embed\/#?secret=I5rCsDcsQl\" width=\"600\" height=\"338\" title=\"&#8220;Global Oncology Trends. L\u2019ultimo report di IQVIA Institute&#8221; &#8212; Frezza Partners\" data-secret=\"I5rCsDcsQl\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/frezzapartners.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2018\/05\/stephen-walker-572414-unsplash-1-1024x667.jpg","thumbnail_width":1024,"thumbnail_height":667,"description":"Photo by Stephen Walker &nbsp; Pi\u00f9 di 700 aziende sono impegnate oggi nella ricerca oncologica. In particolare risultano quattordici le top companies con la maggior parte della pipeline focalizzata su tale area (almeno un terzo).\u00a0 Per quanto concerne gli studi di ricerca, questi sono concentrati specialmente su immunoterapie, con circa trecento molecole e sessanta meccanismi d\u2019azione in valutazione nei trial di fase I e II. Settecento sono i farmaci in pipeline oncologica. Ecco ci\u00f2 che emerge dal report di IQVIA..."}